Antibodies for Cancer Immunology

Cancer immunotherapies exploit subtly different molecules, such as proteins and carbohydrates, on the cell surface of tumor cells, which can be detected by the immune system. Immunotherapy activates the immune system by detecting these molecular antigens and targeting the tumor cells. Immune checkpoint ligands, such as PD-L1, are often times upregulated in tumor cells and using immune checkpoint proteins has become a method to target cancer treatment. Further, targeting immune-checkpoint proteins is another important area of focus as these proteins are often times dysregulated by tumors.

Available Antibodies: PDL1 PDL2 PD1 CD80 CD86 CD28 CTLA4 B7RP1 ICOS B7-H3 B7-H4 HVEM BTLA MHC Class I MHC Class II KIR TCR LAG3 CD137L CD137 OX40L OX40 CD70 CD27 CD40 CD40L GAL9 TIM3 A2aR

Flow Cytometry: CTLA-4 Antibody [AF-386-PB] - NS0 mouse myeloma cell line co-transfected with human CTLA-4 and eGFP was stained with either (A) Goat Anti-Human CTLA-4 Antigen Affinity-purified Polyclonal Antibody (R&D Systems catalog # AF-386-PB) or (B) Normal Goat IgG Control (R&D Systems catalog # AB-108-C) followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (R&D Systems catalog # F0108).

Flow Cytometry: B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/ml. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.